

## Deep Brain Stimulation for Parkinson's Disease – A Review

Christopher R Honey<sup>1</sup> and Manish Ranjan<sup>2</sup>

1. Associate Professor of Neurosurgery, Surgical Centre for Movement Disorders, University of British Columbia, Vancouver;

2. Associate Professor of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bangalore

### Abstract

The majority of patients with Parkinson's disease (PD) can be treated with medications. As the disease progresses, however, certain symptoms may evolve that are refractory to medical therapy but ideally suited to surgical intervention. Tremor, dyskinesia and motor fluctuation can be effectively treated with deep brain stimulation (DBS). This article highlights which PD patients can benefit from DBS and summarises how the operations are performed and what are the expected outcomes (and potential complications). The relevant literature is reviewed for experienced clinicians and our personal bias is highlighted for those new to the field (and hoping to avoid our early mistakes).

### Keywords

Parkinson's disease, deep brain stimulation, tremor, dyskinesia, motor fluctuation, complication, outcome

**Disclosure:** The authors have no conflicts of interest to declare.

**Acknowledgements:** Christopher R Honey would like to acknowledge the patients of British Columbia with Parkinson's disease, who have entrusted their lives to our team. We are honoured to have cared for them, humbled by their bravery and more knowledgeable for having treated them.

**Received:** 2 February 2012 **Accepted:** 23 March 2012 **Citation:** *European Neurological Review*, 2012;7(1):28–34 DOI:10.17925/ENR.2012.07.01.28

**Correspondence:** Christopher R Honey, Surgical Centre for Movement Disorders, University of British Columbia, Suite 8105, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. E: chris.honey@telus.net

*Any surgical procedure requires two things to be successful: selecting the correct patient and performing the operation correctly.*

The various operations of deep brain stimulation (DBS) for Parkinson's disease (PD) are not particularly difficult. They comprise a series of steps that must be performed in an appropriate sequence and can be learned by most neurosurgeons within a year of fellowship training. The selection of the ideal patient, however, is much more difficult and is as much an art as a science.

This article will summarise how DBS can be used to help patients with PD. The relevant literature will be presented for a comprehensive overview but we will focus on our personal experience (and bias) to provide practical guidelines. Each of the three main brain targets for this technique will be discussed and suggestions on patient selection, surgical technique, post-operative care and expected outcomes will be provided.

The current popularity and wide acceptance of DBS for PD began in the early 1990s. Publications from the teams in Grenoble<sup>1,2</sup> and Lille<sup>3</sup> re-ignited interest in this technique after earlier publications had introduced the concept of DBS for PD but had not gained wide acceptance.<sup>4</sup> The concept that DBS could create a beneficial clinical effect without destroying tissue was very appealing. Prior to this technology, neurosurgeons could only destroy target areas in the brain. A variety of structures had been lesioned in an attempt to ameliorate PD, including the motor cortex,<sup>5,6</sup> the spinal cord motor pathways<sup>7</sup> and the basal ganglia.<sup>8</sup> The early experience (prior to 1960) was fraught with morbidity and mortality.<sup>9</sup> The more recent experience has been aided by accurate neuroimaging, intra-operative electrophysiological

confirmation of targeting and reproducible lesioning. During thalamotomy, macrostimulation of the ventral intermediate nucleus (Vim) with high-frequency stimulation (100 Hz) was known to block contralateral tremor whereas 'low'-frequency stimulation (50 Hz) drove the tremor.<sup>2</sup> Permanent implantation of an electrode to chronically stimulate the Vim at high frequency was proposed to suppress tremor<sup>2</sup> and tested as a method to avoid the complications associated with bilateral thalamotomy.<sup>1,10,11</sup> Following a unilateral Vim thalamotomy, the contralateral side could be treated with DBS. Beneficial effects (i.e. blocking tremor) were obtained by increasing the voltage of stimulation and deleterious side effects (e.g. dysarthria) were avoided by reducing the voltage. The effect of DBS could be titrated.

The ability to titrate the effect of DBS has remained its greatest asset. Adjusting the effect of DBS post-operatively to gain more benefit in a progressive disease or back away from a side effect is appealing to both the surgeon and patient. The concept that 'we have not burned any bridges' is also very appealing to many potential patients. Prospective patients often arrive for their surgical consultation emboldened by the concept that the surgeon is 'only' inserting an electrode in their brain and not burning any tissue. The review of potential risks of DBS is often surprising for the patients and is an essential part of their pre-operative assessment.

With the success of Vim DBS in reducing tremor following contralateral thalamotomy, it was not long before DBS was used primarily to treat tremor without any prior thalamotomy.<sup>2</sup> DBS appeared to work like a reversible lesion and was therefore tried in the pallidum instead of pallidotomy.<sup>12</sup> At this time, surgeons began exploring the subthalamic nucleus (STN) as a target for PD and DBS

was used in this target prior to any significant experience with lesions in this target.<sup>13,14</sup>

How DBS exerts its effects remains controversial.<sup>9,15-20</sup> Since high-frequency DBS in the thalamus or pallidum had similar clinical effects to lesions, it was assumed that DBS worked by inhibiting neuronal firing. This reasoning was used to support surgeons targeting the STN, which had been shown to be overactive in primate models of PD.<sup>21,22</sup> More recently, however, it has become clear that the effect is probably more complex.<sup>9</sup> DBS may work by desynchronising pathological rhythms in the basal ganglia.<sup>23</sup>

DBS brings a new set of problems to the management of PD. There are complications associated with surgery (brain haemorrhage and infection),<sup>9,24-28</sup> stimulation-related and neuropsychiatric issues.<sup>29,30</sup> There is the need for intensive follow-up care to adjust the stimulation and the technology is expensive. Nonetheless, the ideal patient receiving the ideal operation can enjoy stunning benefits.<sup>31-33</sup> It all begins with selecting the correct patient.<sup>34-38</sup>

### Patient Selection

*The surgeon must aim to improve the quality of life of their patient not just reduce a given symptom.*

The majority of patients with PD are adequately managed with medications.<sup>39</sup> A small portion of patients, however, will have medically refractory symptoms that can be ameliorated with surgery. The selection of these patients is just as important as the performance of surgery in determining the final outcome. The general neurosurgeon does not require help assessing the need for surgery in a patient with a traumatic epidural haematoma or tumour causing brain herniation. What is the alternative? The functional neurosurgeon, however, must be satisfied that the medical alternatives have failed before considering surgery. This presents a problem for the neurosurgeon unfamiliar with PD medications. The solution in many centres has been a close collaboration between the neurosurgeon, neurologist and other specialists.<sup>33,34,40</sup> This is a recurring theme in DBS for PD – it requires a team to deliver ideal care.

Patients referred from family doctors for DBS (often at the request of the patient) are often just not optimised with their medications and are therefore not surgical candidates. For example, a patient referred for surgery because of disabling dyskinesia may benefit from a reduction in their medications or the addition of amantadine.<sup>41,42</sup> It has been our practice to ensure all patients referred for surgery have had a consultation with a neurologist familiar with the treatment of PD. This reduces the proportion of surgical consultations that are not yet appropriate candidates for surgery. If the family practitioner must be careful not to refer patients for surgery too soon, the neurologist must be careful not to refer patients too late. End-stage PD is refractory to maximal available therapy.<sup>43</sup> Loss of response to oral dopamine often parallels a lack of response to STN or globus pallidus internus (GPI) DBS<sup>36,37</sup> (although Vim DBS may continue to be effective). It is clear that there is a window of opportunity for successful DBS for PD.<sup>35</sup> Early in the disease, medications are effective and surgery is unnecessary. Later in the disease, surgery may help certain symptoms and improve quality of life (the subject of this article). Finally, for some patients in the end stage of the disease, neither medications nor surgery can help.<sup>43,44</sup> Neurologists must not wait until the end stage of PD before considering a surgical referral because the surgery would be

ineffective (and not offered). When to make a surgical referral will be influenced by the neurologist's impression of the balance between the degree of patient suffering and their neurosurgical colleague's complication rate. When does a symptom warrant surgical intervention? The answer ultimately lies with the patient. They can estimate what the quality of their life would be like after surgery (once the surgeon explains the expected benefits) and balance this against the chance of their life being worse due to complication. The neurologist can increase the likelihood of success, first by selecting patients whose quality of life will improve dramatically after surgery, and second by selecting a surgeon with a low complication rate.

When a patient arrives for surgical consideration of DBS for PD there are two questions that must be answered in sequence. First, are they a surgical candidate? This is answered by the neurosurgeon after determining if the symptoms interfering with the patient's quality of life can only be improved with surgery. Only after that determination should the second question be posed. Do they want surgery? The second question can only be answered by the patient once they understand the expected benefits and potential risks of surgery. At the present time, there are three types of patients who can benefit dramatically from DBS for PD. Each of the three corresponds to a different DBS brain target: the thalamus, the pallidum and the STN.

### Tremor-dominant Parkinson's Disease (Thalamic Deep Brain Stimulation)

Every patient with PD has a constellation of symptoms that affect them in a unique way. Although each patient is different, certain patterns emerge across the disease.<sup>45</sup> Two distinct patterns can be recognised by their different clinical features and neuropathological findings.<sup>45,46</sup> 'Tremor-dominant' patients have a slower progression of symptoms and can be disabled by tremor and yet still remain mobile with medications. 'Akinetic-rigid' patients have a faster progression, more cognitive impairments and develop motor complications with or without tremor. For patients with tremor-dominant PD, thalamic DBS can be considered if their tremor is disabling. These patients can present for surgical consideration a decade after their diagnosis and still on relatively low doses of medications. Their clinical course does not appear to be rapidly changing. The slope of their clinical deterioration is shallow and therefore their future quality of life can be reasonably predicted by extrapolating their progression of symptoms forwards. Tremor in these patients can be severe and is often the overwhelming factor in their reduced quality of life.<sup>36,45,47</sup>

Tremor occurs at rest but can become exhausting. The tremor will dampen on the initiation of movement but, as the arm is held still for any activity (e.g. holding a cup to the lips), the arm will shake again. This tremor can be present in the upper and lower limb as well as the jaw and body. What degree of tremor is intolerable will depend entirely on the patient. The retired teacher can tolerate more tremor than when they were working. Our policy has been to defer to the patient but, in general, we would consider thalamic DBS once the tremor interferes with employment or activities of daily living such as eating, personal hygiene or dressing. The selection of left, right or bilateral procedures is entirely individual. In general, we recommend a unilateral procedure for the dominant hand in patients who have retired from working (typically aged 65). After six months to a year, the patient will know the result of what their thalamic DBS can do and how it affects their unique activities. If they want the opposite side done, they can have it as a staged procedure. For patients still in the workforce, a bilateral procedure is often performed initially.

### Disabling Dyskinesia (Globus Pallidus Deep Brain Stimulation)

The first few years of medical treatment of PD can often produce excellent results.<sup>39</sup> Patients feel dramatically better on medications and are not disabled. As the disease progresses, however, new complications emerge: dyskinesia and motor fluctuations.<sup>39,48,49</sup> Dyskinesia is a side effect of dopaminergic stimulation. Its aetiology is unknown but its manifestations are unmistakable. Patients can be affected over a wide range of severity. Mild dyskinesia is a smooth, near-constant movement perhaps best described as wiggling (like a bored young child) and can be deliberately hidden by patients within normal movements (e.g. adjusting clothing). The patient may become unaware of this movement but the spouse can often notice it. Dyskinesia can gradually increase in severity (it is measured on a scale of 0–4)<sup>50</sup> and patients find moderate dyskinesia intrusive. At this stage, patients will often walk with their arm(s) pulled behind them in a writhing movement. Severe dyskinesia is ballistic and dangerous. Patients can throw themselves out of a chair, injure bystanders and find the constant movement exhausting. They will lose weight from the constant exercise and any joint simultaneously affected with arthritis will be excruciatingly painful. The first treatment for dyskinesia is to reduce the PD medications.<sup>51</sup> Reduced medications, however, will produce more bradykinetic symptoms (unless initially overdosed) and patients will invariably choose dyskinesia over bradykinesia. For the patient with disabling dyskinesia superimposed upon otherwise good control of their motor symptoms, globus pallidus DBS is an option. This treatment requires the neurologist to maintain the PD medications (and even increase if necessary) to manage mobility, while the globus pallidus DBS controls the dyskinesia. The neurologist is free to push medications harder because the previous limiting side effects (dyskinesia) have been removed by the DBS.

### Motor Fluctuations (Subthalamic Deep Brain Stimulation)

The beneficial effect of a given dosage of PD medication tends to last for a shorter period as the disease progresses.<sup>52</sup> This is initially overcome by shortening the dosage interval. Eventually some patients are taking their PD medications every three hours and still not getting consistent benefit. They usually report that it takes a variable amount of time for the medications to start working (30–60 minutes after swallowing), then they get benefit for an hour which then starts to wear off before the next dosage. Patients will therefore fluctuate in their symptoms from bradykinetic-rigid to moving well to peak-dose dyskinesia, then back to moving well and finally bradykinetic-rigid. This cycle is repeated with each dose. This pattern is called motor fluctuations<sup>39</sup> and can be ideally treated with STN DBS.

It is our opinion that the effect of STN DBS mimics that of dopaminergic medication except that it can be applied smoothly throughout the day instead of in dosing intervals. The ideal patient will therefore have enjoyed a good response to dopaminergic medications pre-operatively. That response may be partially obscured by dyskinesia or motor fluctuations but there must be one moment in a typical day when the patient has a good response to the medications. If that is the case, then STN DBS will be able to 'capture' that moment and extend it longer throughout the day. Patients will not have a better motor function than before surgery; they will just spend more time at that best level of functioning. Patients who have motor problems when they are at their best (i.e. when they are 'on') are therefore not good candidates for STN DBS. Patients with freezing or imbalance when on will continue to have those problems after STN DBS.<sup>53–55</sup> Conversely, if their 'off' freezing,

tremor, rigidity or balance problems improve with medications then those symptoms will improve following STN DBS. The adjustment of the DBS parameters following STN DBS is the most complicated of the three brain targets and can induce unwanted side effects.<sup>29,56–58</sup>

### The Surgical Technique of Deep Brain Stimulation

*Surgeons make errors at the beginning of their career when they are on the learning curve and later in their career when they are not paying attention.*

There is a learning curve for performing DBS for PD. We would recommend that surgeons spend their first 30 cases in an environment where an expert can mentor them and pre-empt any learning errors. Lapses in concentration can be avoided by obsessively following a reliable sequence of events. Unfortunately, the checklists designed to prevent our orthopaedic colleagues from removing the wrong limb are not detailed enough for functional neurosurgery. We have found that the constant intra-operative teaching of a fellow (and providing an environment where anyone can raise a concern) reinforces following the correct operative steps.

All DBS techniques for PD begin with imaging the brain target and calculating its location with an external reference grid that can be used to guide the electrode into the target.<sup>2,59–62</sup> This can be performed in many ways. Each method has strengths and weaknesses but none can claim an overall accuracy of less than 1 mm. The current gold standard (based on historical precedent, number of annual cases and peer-reviewed evaluations) is frame-based magnetic resonance imaging (MRI) stereotaxis.<sup>63</sup> We acknowledge that there are many centres producing excellent work with frameless technology<sup>64–68</sup> and remember that all of our early work was carried out with ventriculography and computed tomography (CT) guidance.<sup>2,69</sup> How you perform your stereotaxis is not as important as doing it well. Our procedure is to place the frame pre-operatively under local anaesthetic and then perform an MRI. The ideal sequence for visualising the brain target will vary between machines but guidelines have been published.<sup>69–80</sup> Some centres perform the MRI as an out-patient to allow pre-operative planning in the office and some centres use both the CT and MRI imaging.<sup>69,81,82</sup> Some centres have used general anaesthetic<sup>83–85</sup> and reported good results. Ultimately, how you image the target is not as important as your ability to reliably get to within 1–2 mm of the ideal location. The final electrode position will be refined with intra-operative electrophysiology.<sup>72,86,87</sup>

The anatomical target can be determined by its expected position relative to standard internal landmarks or by directly visualising it. The standard internal landmark is the mid-point (MCP) of a line between the anterior (AC) and posterior (PC) commissures. The locations of the AC and PC can be difficult to determine in some patients if they are elongated vertically in the sagittal plane, but it is important to select the posterior aspect of the AC and the anterior aspect of the PC, since these co-ordinates were developed when ventriculography was used (when you saw the indentation of the AC into the third ventricle, not the actual AC). Image quality will be degraded by motion artefacts and we avoid dyskinesia in GPi and STN DBS patients by withholding their PD medications the night before surgery and blocking tremor with judicious use of intravenous midazolam during the MRI.

Images are then uploaded to a neuronavigational computer for trajectory planning. The neuronavigational computer has two benefits. Firstly, it can

realign the brain so that the AC and PC lie on the same axial plane (regardless of how the frame was applied). Moving away from the MCP towards the target can then be performed accurately because the frame has not introduced a pitch, roll or yaw error.<sup>72,88,89</sup> Prior to neuronavigational computers, it was crucial to apply the frame parallel to the AC–PC to avoid these errors. We believe it continues to be good practice to place the frame orthogonal to the AC–PC line, using the glabella–inion or infra-orbital–meatal lines as a guide. Secondly, it allows a trial of virtual electrode passes through the brain to determine if any would pass through a blood vessel, sulcus or ventricle.<sup>88</sup> We perform a thin-cut T1-weighted sequence with gadolinium and use a 'probe's eye view' to ensure no vessel would be hit during our electrode pass. This step is time-consuming but is probably the single most important improvement in technique over the last decade that has reduced complications.

During the surgery, there are a set of common surgical techniques regardless of the target and some specific nuances for each. It is our practice to place patients supine on the operating table, flexed at the hips and knees and head elevated with the skull at the entry site almost horizontal. This places the skull above the heart and risks venous air emboli when close to the midline (thalamic approach). In one review,<sup>90</sup> the incidence of air embolism was reported to be up to 3.2%. Clinically symptomatic emboli, however, are rarely reported.<sup>91,92</sup> In our experience, if emboli occur, the awake patient will begin to clear their throat (and describe a tickle in their throat) and later cough. This occurs concurrently when, or slightly before, a pre-cordial Doppler detects the emboli and lasts longer than the Doppler detection. We do not use a pre-cordial Doppler but respond quickly – waxing the bone and flooding the area with irrigation – if patients suddenly begin to clear their throats. The procedure is performed under local anaesthetic (a mixture of short- and long-lasting) and patients are not routinely given sedatives. Blood pressure is maintained below 140 mmHg systolic with antihypertensives selected not to interfere with the operation ( $\beta$ -blockers will stop tremor and some e.g. metoprolol<sup>93</sup> can reduce STN bursting). We use hydralazine and labetalol (when tremor is not an issue). Patients have pneumatic intermittent calf compression and females are catheterised. The opening of the skull deserves attention. Scalp incisions are made to best avoid hardware directly beneath them.<sup>94</sup> This lesson has been adopted from our paediatric neurosurgical colleagues and their vast experience with shunts but has been lost to some surgeons who continue to use a straight incision (best suited for lesions) even after transitioning to DBS. Care is taken to preserve the arachnoid when opening the dura. The arachnoid is then coagulated down onto the pia and 'spot welded' so the pial incision does not cause a cerebrospinal fluid (CSF) leak. We believe this simple technique reduces brain shift during surgery.<sup>95</sup> After the electrodes are placed through the brain, the burr hole is sealed with Surgifoam® (Ferrosan Medical Devices, Soeborg, Denmark) and Tisseel® (Baxter, Vienna, Austria).

### Thalamic Deep Brain Stimulation

The thalamic target is the Vim. Some authors<sup>96</sup> describe a deeper target, the zona incerta, which probably catches the fibres heading to the Vim as a smaller bundle. Recent diffusion tensor imaging suggests that the dentatorubrothalamic fibres can be targeted at a variety of levels to obtain a similar tremor reduction.<sup>97</sup> The Vim lies immediately in front of the sensory ventral caudal (Vc) nucleus and can be estimated from its position relative to the MCP. Direct visualisation, although described by our group,<sup>98</sup> has not become popular with conventional MRI. All our intra-operative electrophysiology is performed with macroelectrode stimulation. We acknowledge that micro-electrode recording adds to the

scientific discoveries in our field but are not convinced it adds any accuracy to this operation (it can certainly add morbidity).<sup>99,100</sup>

The deepest point for the Vim nucleus (and thus its target for the tip of the DBS electrode) is as follows:

- X (lateral) = 11 mm from edge of third ventricle;
- Y (anteroposterior) = halfway between MCP and PC; and
- Z (vertical) = at the level of AC–PC.

We prefer to approach at an angle of 65° up from the AC–PC line in the sagittal plane and close to vertical in the coronal plane. Although a vertical approach in the coronal plane is ideal for thalamotomy, it does present risks for thalamic DBS (e.g. injuring periventricular veins, electrode deflection off the side wall of the ventricle and CSF leakage). The benefit of a vertical approach is that it keeps the electrode as far away as possible from the internal capsule (and its resultant stimulation-induced side effects) and it keeps the electrode in the hand region of the nucleus without deviating into a different part of the homunculus as you move deeper. The final decision is made individually, but primarily in response to the location of periventricular veins.

Intra-operative electrophysiological confirmation of the target is performed with a macroelectrode (Radionics 1.5 mm exposed tip, 1.8 mm diameter). The stimulation parameters will vary between equipment but 50 Hz, 1 ms pulses at 1.0 V (typically 500  $\Omega$ ) will just begin to cause paraesthesia in the thumb (Vc) when the electrode tip is appropriate in Vim. This will confirm both anteroposterior location (<1.0 V is too close to Vc) and laterality (paraesthesia in face is too medial). High-frequency stimulation (180 Hz at 0.1 ms) should block tremor at 1.0 V without side effects. The macroelectrode can then be replaced by a permanent DBS electrode under fluoroscopic guidance and locked in place. The scalp wound is closed, the frame removed and the implantable neural stimulator (INS) placed under general anaesthetic during the same operation. We do not test the electrode on the ward before implanting the INS because we have never had a good intra-operative response that was not duplicated post-operatively and a prolonged trial on the ward invites infection.

The second stage of the procedure (implantation of the INS) can be performed in many ways but we prefer keeping the connector (joint between the electrode and extension wire) high up near the burr hole and tunnelling from the scalp to the infraclavicular location with an exit wound behind the ear. The connector is covered with a waterproof boot (clear for right and opaque for left) and sutured to exclude fluid. Patients receive antibiotics before surgery and for 24 hours after.

### Pallidal Deep Brain Stimulation

The pallidal target is the GPI. The GPI lies immediately above the optic tract and lateral to the internal capsule. Direct visualisation can guide targeting,<sup>71,79,88,101,102</sup> although many groups still use co-ordinates relative to the MCP. As in the thalamus, we have not found that micro-electrode recording has added to the operation and a meta-analysis suggested it increased the risk of complications.<sup>99,100</sup>

The deepest point for the GPI nucleus (and thus its target for the tip of the DBS electrode) relative to the MCP is as follows:

- X (lateral) = 21 mm lateral from the midline;
- Y (anteroposterior) = 2 mm anterior; and
- Z (vertical) = 4–6 mm below.

We adjust the initial anatomical target to be as inferior as possible but still 2 mm superior to the dorsolateral edge of the optic tract. We prefer to approach at an angle of 65° up from the AC–PC line in the sagittal plane and often are 10–20° lateral in the coronal plane in order to come through the middle frontal gyrus and avoid sulci.

Intra-operative electrophysiological confirmation of the GPI target is performed with a macroelectrode (Radionics 1.5 mm exposed tip, 1.8 mm diameter). The stimulation parameters will vary between equipment but 50 Hz, 1 ms pulses at 3.0–5.0 V (typically 900 Ω) will cause contralateral hand or face contractions (or paraesthesia) due to internal capsule stimulation. There is no symptom to titrate the DBS against because patients will not have dyskinesia during surgery, since their PD medications will have been held from the night before. The macroelectrode can then be replaced by a permanent DBS electrode under fluoroscopic guidance and locked in place. Placement of the INS is the same as for the thalamic procedure described above.

### Subthalamic Nucleus Deep Brain Stimulation

The STN target is relatively small<sup>103–105</sup> and its dorsolateral portion appears to be the ideal target.<sup>106–110</sup> Many groups use direct visualisation of the target with T2-weighted magnetic resonance images that show the presumed location of the nucleus as dark, low signal intensity because of its expected iron content.<sup>72,75,111</sup> We have used a combination of micro-electrode recording and macrostimulation to electrophysiologically confirm the ideal electrode site.

The deepest point for the STN target (and thus its target for the tip of the DBS electrode) relative to the MCP is as follows:

- X (lateral) = 11 mm lateral from the midline;
- Y (anteroposterior) = 3 mm posterior; and
- Z (vertical) = 4 mm below.

We adjust the initial anatomical target based on the MRI by selecting a point in the medial edge of the STN (in line with the anterior border of the red nucleus at its equator). We prefer to approach at an angle of 65° up from the AC–PC line in the sagittal plane and are often 10–20° lateral in the coronal plane in order to come lateral to the ventricles but medial to the inferior frontal sulcus.

Intra-operative electrophysiological confirmation of the STN is performed with an array of micro-electrodes.<sup>72,112–119</sup> We use a fixed array of three micro-electrodes: a 'centre' electrode aimed at the target, another 2 mm 'lateral' and a third 2 mm 'anterior' to the centre. The simultaneous use of an electrode array (often five at a time) is more popular in Europe than in North America.<sup>120</sup> Its advantage is that the brain does not move when switching from one recording to the next and the brain is held in place when the micro-electrode is replaced with the permanent lead. The concept that multiple electrodes would increase the risk of haemorrhage<sup>121</sup> has not been shown in larger multi-centred series.<sup>122</sup> Once we have mapped out the vertical extent of the STN with the three electrodes, we will choose a dorsolateral site within the STN for macrostimulation. If contralateral wrist rigidity is reduced with 0.5–1.0 mA, 130 Hz and 0.1 ms and no side effects are encountered at 3.0 mA, that macroelectrode can then be replaced by a permanent DBS electrode under fluoroscopic guidance and locked in place. Placement of the INS is the same as for the thalamic procedure described above except patients are given their morning dose of PD medications before the general anaesthetic.

### Outcome – Benefits and Complications

*Symptom control may satisfy the surgeon but improvement in quality of life is what satisfies the patient.*

If the patient's expectations are met, then they will be satisfied with the outcome of the operation. Setting appropriate expectations and then meeting them is a complex process. Firstly, the symptom causing reduced quality of life must be addressed. Secondly, the patient must be educated as to what are the realistic results of surgery. Finally, the surgery must be performed correctly. Lapses in any of these steps will result in unsatisfied patients. For example, tremor reduction of 80 % in someone expecting perfection will leave the patient unhappy and the surgeon wondering why.

The complications of DBS for PD are both general (related to placing an electrode in the brain) and target-specific (related to stimulation-induced side effects). Pushing the electrode through the brain can tear a blood vessel and cause bleeding. We have had no deaths but two symptomatic haemorrhages in 400 cases (0.5 %). Even a small bleed can result in catastrophic disability because the patients are already maximally compromised and have no ability to compensate. The literature reports death (1–2 %)<sup>121,123–125</sup> and haemorrhage (0.7–3.1 %)<sup>24,126</sup> at varying rates. Placing a foreign object under the skin of an immunocompromised elderly individual invites infection and skin erosion. Infections and/or skin erosion are relatively common (1–15 %).<sup>125–128</sup> Device failure is uncommon,<sup>129,130</sup> but fractures in the leads and extensions can occur, especially if misplaced.

The literature has focused on reporting symptom reduction rather than patient satisfaction. Symptom reduction can be quantified and therefore comparisons can be made between techniques and centres and used for recommendations.

### Thalamic Deep Brain Stimulation

In 1993, Benabid et al.<sup>131</sup> reported 88 % of PD patients obtained 'good' or 'excellent' reduction of tremor. Multi-centre trials from North America<sup>132</sup> (58 % of patients had total tremor resolution) and Europe<sup>133</sup> (85 % of patients had contralateral tremor reduced by at least 2 points on the unified Parkinson's disease rating scale UPDRS tremor score of 0–4) confirmed the results. The results appear to be long-lasting.<sup>61,134</sup> An initial review of the literature makes it clear that direct comparisons are difficult but a common theme emerges. DBS can reduce tremor in PD and the effects continue for at least five years. The magnitude of tremor reduction varies from patient to patient but averages an 80 % reduction. This is typically enough to allow a PD patient to feed, clothe and clean themselves. Stimulation of Vim can be associated with dysarthria and paraesthesia, which are rarely disabling and usually reversible with the adjustment of stimulation parameters.<sup>2</sup>

### Pallidal Deep Brain Stimulation

In 1994, Siegfried et al.<sup>12</sup> suggested DBS in the pallidum as a new therapeutic approach to alleviating all parkinsonian symptoms. They reported excellent improvement of motor symptoms and near-total elimination of levodopa-induced dyskinesia with pallidal stimulation in three patients with advanced PD. Various groups subsequently suggested similar experience with GPI DBS and reported improvement in the UPDRS off motor score by 31–58 %<sup>135,136</sup> and improvement of dyskinesia by 64–76 %.<sup>137,138</sup> These effects are long-lasting and improved the activities of daily living (ADL) scores.<sup>135–138</sup> The safety and effectiveness of GPI DBS for PD was further consolidated by the

prospective randomised blinded study<sup>121</sup> and prospective long-term follow-up studies.<sup>62,139</sup> The specific complication with GPI DBS can be neuropsychological changes, disturbance in sleep pattern and dysarthria; however, these are relatively infrequent.<sup>140</sup>

### Subthalamic Nucleus Deep Brain Stimulation

STN DBS for PD was first reported by the Grenoble group in France.<sup>131a</sup> A later randomised trial showed that STN DBS was more effective than the best medical therapy in advanced PD with significant improvement in the UPDRS-III and Parkinson's disease questionnaire (PDQ-39) (Quality of life).<sup>31</sup> Benefits are consistent between the groups and can persist for four to ten years.<sup>31,121,139,141</sup> STN DBS improves all the cardinal dopaminergic symptoms. It requires a significant reduction in dopaminergic medication and therefore reduces medicine-related adverse effects.<sup>14,142–144</sup> In a meta-analysis of outcomes following STN DBS,<sup>145</sup> it was found that the average decrease in absolute UPDRS II (activities of daily living) was 13.35. The average reduction in L-dopa equivalents following surgery was 55.9 % and the average reduction in dyskinesia following surgery was 69.1 %. It was also noted that the average decrease in the duration of daily off periods was 68.2 % and the average improvement in quality of life was improved to 34.5 %. However, post-operative management of STN DBS

is the most complex of the three targets; stimulation-induced side effects include neuropsychological and behavioural complications, notably suicide and hypomania.<sup>29,30,146</sup>

### Conclusions

DBS has quickly become the favoured treatment for specific symptoms of PD in nations that can afford the technology. The benefits of DBS (post-operative titration of effect) outweigh its disadvantages (infection and expense) in correctly selected patients. Lesions (pallidotomy and thalamotomy) continue to have a role in the management of PD, but future research into the surgical treatment of PD will probably centre around DBS. New targets, such as the pedunculo-pontine nucleus, have generated interest and publications but not yet gained widespread acceptance. Neurosurgeons will no doubt be emboldened by the concept that DBS modifies rather than destroys brain activity as they try to ameliorate the symptoms of PD, regardless of the location of new targets or the complexity of the operation designed to get there. Selecting the correct patient for the procedure will remain of paramount importance. The close collaboration between neurologist and neurosurgeon for the optimum management of their PD patients continues to be an excellent model for the provision of care in the neurosciences. ■

1. Benabid AL, Pollak P, Louveau A, et al., Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease, *Appl Neurophysiol*, 1987;50:344–6.
2. Benabid AL, Pollak P, Gervason C, et al., Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus, *Lancet*, 1991;337:403–6.
3. Blond S, Siegfried J, Thalamic stimulation for the treatment of tremor and other movement disorders, *Acta Neurochir Suppl (Wien)*, 1991;52:109–11.
4. Cooper IS, Upton AR, Amin I, Chronic cerebellar stimulation (CCS) and deep brain stimulation (DBS) in involuntary movement disorders, *Appl Neurophysiol*, 1982;45:209–17.
5. Horsley V, Remarks on the surgery of the central nervous system, *Br Med J*, 1890;2:1286–92.
6. Cobb S, Pool JL, Scarff J, et al., Section of U fibers of motor cortex in cases of paralysis agitans (Parkinson's disease); report of 9 cases, *Arch Neurol Psychiatry*, 1950;64:57–9.
7. Putnam TJ, Relief from unilateral paralysis agitans by section of the pyramidal tract, *Arch Neurol Psychiatry*, 1938;40:1049–50.
8. Meyers R, A surgical procedure for the alleviation of postencephalitic tremor, with notes on the physiology of the premotor fibres, *Arch Neurol Psychiatry*, 1940;44:455–9.
9. Benabid AL, Chabardes S, Torres N, et al., Functional neurosurgery for movement disorders: a historical perspective, *Prog Brain Res*, 2009;175:379–91.
10. Cooper IS, Neurosurgical treatment of the dyskinesias, *Clin Neurosurg*, 1977;24:367–90.
11. Matsumoto K, Asano T, Baba T, et al., Long-term follow-up results of bilateral thalamotomy for parkinsonism, *Appl Neurophysiol*, 1976;39:257–60.
12. Siegfried J, Lippitz B, Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms, *Neurosurgery*, 1994;35:1126–9.
13. Pollak P, Benabid AL, Gross C, et al., Effects of the stimulation of the subthalamic nucleus in Parkinson disease, *Rev Neurol (Paris)*, 1993;149:175–6.
14. Benabid AL, Pollak P, Gross C, et al., Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease, *Stereotact Funct Neurosurg*, 1994;62:76–84.
15. Filali M, Hutchison WD, Palter VN, et al., Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus, *Exp Brain Res*, 2004;156:274–81.
16. Benabid AL, Benazzous A, Pollak P, Mechanisms of deep brain stimulation, *Mov Disord*, 2002;17(Suppl. 3):S73–4.
17. Welter ML, Houeto JL, Bonnet AM, et al., Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients, *Arch Neurol*, 2004;61:89–96.
18. Xia R, Berger F, Pliatt B, Benabid AL, Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation, *Acta Neurochir (Wien)*, 2007;149:67–73.
19. Meissner W, Leblois A, Hansel D, et al., Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations, *Brain*, 2005;128:2372–82.
20. Tai CH, Boraud T, Bezard E, et al., Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridges neuronal activity in the subthalamic nucleus and the substantia nigra reticulata, *FASEB J*, 2003;17:1820–30.
21. Aziz TZ, Peggs D, Sambrook MA, Crossman AR, Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate, *Mov Disord*, 1991;6:288–92.
22. Bergmann H, Wichmann T, Delong MR, Reversal of experimental parkinsonism by lesions of the subthalamic nucleus, *Science*, 1990;249:1436–8.
23. Wilson CJ, Beverlin B, Netoff T, Chaotic desynchronization as the therapeutic mechanism of deep brain stimulation, *Front Syst Neurosci*, 2011;5:50.
24. Binder DK, Rau G, Starr PA, Hemorrhagic complications of microelectrode-guided deep brain stimulation, *Stereotact Funct Neurosurg*, 2003;80:28–31.
25. Bhatia S, Zhang K, Oh M, et al., Infections and hardware salvage after deep brain stimulation surgery: a single-center study and review of the literature, *Stereotact Funct Neurosurg*, 2010;88:147–55.
26. Binder DK, Rau GM, Starr PA, Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders, *Neurosurgery*, 2005;56:722–32.
27. Lyons KE, Wilkinson SB, Overman J, Pahwa R, Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures, *Neurology*, 2004;63:612–6.
28. Vergani F, Landi A, Pirillo D, et al., Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease, *World Neurosurg*, 2010;73:338–44.
29. Coenen VA, Honey CR, Hurwitz T, et al., Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson's disease, *Neurosurgery*, 2009;64:1106–14.
30. Voon V, Kubu C, Krack P, et al., Deep brain stimulation: neuropsychological and neuropsychiatric issues, *Mov Disord*, 2006;21(Suppl. 14):S305–27.
31. Deuschl G, Schade-Brittinger C, Krack P, et al., A randomized trial of deep-brain stimulation for Parkinson's disease, *N Engl J Med*, 2006;355:896–908.
32. Diamond A, Jankovic J, The effect of deep brain stimulation on quality of life in movement disorders, *J Neurol Neurosurg Psychiatry*, 2005;76:1188–93.
33. Moro E, Lang AE, Criteria for deep-brain stimulation in Parkinson's disease: review and analysis, *Expert Rev Neurother*, 2006;6:1695–105.
34. Bronstein JM, Tagliati M, Alterman RL, et al., Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues, *Arch Neurol*, 2011;68:165.
35. Lang AE, Widner H, Deep brain stimulation for Parkinson's disease: patient selection and evaluation, *Mov Disord*, 2002;17(Suppl. 3):S94–101.
36. Lang AE, Houeto JL, Krack P, et al., Deep brain stimulation: preoperative issues, *Mov Disord*, 2006;21(Suppl. 14):S171–96.
37. Rodriguez RL, Fernandez HH, Haq I, Okun MS, Pearls in patient selection for deep brain stimulation, *Neurologist*, 2007;13:253–60.
38. Defer GL, Widner H, Marie RM, et al., Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD), *Mov Disord*, 1999;14:572–84.
39. Sillay KA, Starr PA, Deep Brain Stimulation in Parkinson's Disease. In: Krames ES, Peckham PH, Rezaei AR (eds), *Neuromodulation*, 1st edition, vol. 2, Oxford, UK: Elsevier, 2009;539–48.
40. Kenney C, Simpson R, Hunter C, et al., Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders, *J Neurosurg*, 2007;106:621–5.
41. Del Dotto P, Pavese N, Gambaccini G, et al., Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study, *Mov Disord*, 2001;16:515–20.
42. Metman LV, Del Dotto P, LePoole K, et al., Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study, *Arch Neurol*, 1999;56:1383–6.
43. Ahlskog JE, Beating a dead horse: dopamine and Parkinson disease, *Neurology*, 2007;69:1701–11.
44. Poewe W, The natural history of Parkinson's disease, *J Neurol*, 2006;253(Suppl. 7):VI12–6.
45. Rajput AH, Voll A, Rajput ML, et al., Course in Parkinson disease subtypes: A 39-year clinicopathologic study, *Neurology*, 2009;73:206–12.
46. Jellinger KA, Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms?, *J Neural Transm Suppl*, 1999;56:1–29.
47. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R, The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease, *Qual Life Res*, 1995;4:241–8.
48. Colosimo C, De Michele M, Motor fluctuations in Parkinson's disease subtypes: A 39-year clinicopathologic study, *Neurology*, 1999;6:1–21.
49. Ahlskog JE, Muentner MD, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, *Mov Disord*, 2001;16:448–58.
50. Goetz CG, Stebbins GT, Shale HM, et al., Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment, *Mov Disord*, 1994;9:390–4.
51. Van Gerpen JA, Kumar N, Bower JH, et al., Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990, *Arch Neurol*, 2006;63:205–9.
52. Schrag A, Quinn N, Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study, *Brain*, 2000;123:2297–305.
53. Ianssek R, Rosenfeld JV, Huxham FE, Deep brain stimulation of the subthalamic nucleus in Parkinson's disease, *Med J Aust*, 2002;177:142–6.
54. Landi A, Parolin M, Piolti R, et al., Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza, *Neurol Sci*, 2003;24(Suppl. 1):S43–4.
55. Welter ML, Houeto JL, Tezenas du Montcel S, et al., Clinical predictive factors of subthalamic stimulation in Parkinson's disease, *Brain*, 2002;125:575–83.
56. Deuschl G, Herzog J, Kleiner-Fisman G, et al., Deep brain stimulation: postoperative issues, *Mov Disord*, 2006;21(Suppl. 14):S219–37.
57. Volkmann J, Moro E, Pahwa R, Basic algorithms for the programming of deep brain stimulation in Parkinson's disease, *Mov Disord*, 2006;21(Suppl. 14):S284–9.
58. Thobois S, Corvaisier S, Mertens P, et al., The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation, *Eur Neurol*, 2003;49:59–63.
59. Spiegel EA, Wycis H, Marks M, Stereotactic apparatus for operations in the human brain, *Science*, 1947;106:349–50.
60. Machado A, Rezaei AR, Kopell BH, et al., Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management, *Mov Disord*,

- 2006;21(Suppl. 14):S247-58.
61. Reihncrona S, Johnels B, Widner H, et al., Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments, *Mov Disord*, 2003;18:163-70.
  62. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al., Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up, *Brain*, 2005;128:2240-9.
  63. Hemm S, Wardell K, Stereotactic implantation of deep brain stimulation electrodes: a review of technical systems, methods and emerging tools, *Med Biol Eng Comput*, 2010;48:611-24.
  64. Balachandran R, Mitchell JE, Dawant BM, Fitzpatrick JM, Accuracy evaluation of microTargeting Platforms for deep-brain stimulation using virtual targets, *IEEE Trans Biomed Eng*, 2009;56:37-44.
  65. Bjartmarz H, Reihncrona S, Comparison of accuracy and precision between frame-based and frameless stereotactic navigation for deep brain stimulation electrode implantation, *Stereotact Funct Neurosurg*, 2007;85:235-42.
  66. D'Haese PF, Cetinkaya E, Konrad PE, et al., Computer-aided placement of deep brain stimulators: from planning to intraoperative guidance, *IEEE Trans Med Imaging*, 2005;24:1469-78.
  67. Eljamel MS, Tulley M, Spillane K, A simple stereotactic method for frameless deep brain stimulation, *Stereotact Funct Neurosurg*, 2007;85:6-10.
  68. Holloway KL, Gaede SE, Starr PA, et al., Frameless stereotaxy using bone fiducial markers for deep brain stimulation, *J Neurosurg*, 2005;103:404-13.
  69. Rezaei AR, Kopell BH, Gross RE, et al., Deep brain stimulation for Parkinson's disease: surgical issues, *Mov Disord*, 2006;21(Suppl. 14):S197-218.
  70. Hariz MI, Krack P, Melville R, et al., A quick and universal method for stereotactic visualization of the subthalamic nucleus before and after implantation of deep brain stimulation electrodes, *Stereotact Funct Neurosurg*, 2003;80:96-101.
  71. Pinski MO, Volkman J, Falk D, et al., Electrode implantation for deep brain stimulation in dystonia: a fast spin-echo inversion-recovery sequence technique for direct stereotactic targeting of the GPI, *Zentralbl Neurochir*, 2008;69:71-5.
  72. Starr PA, Christine CW, Theodosopoulos PV, et al., Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations, *J Neurosurg*, 2002;97:370-87.
  73. Aziz TZ, Nandi D, Parkin S, et al., Targeting the subthalamic nucleus, *Stereotact Funct Neurosurg*, 2001;77:87-90.
  74. Liu X, Rowe J, Nandi D, et al., Localisation of the subthalamic nucleus using Radionics Image Fusion and Stereoplan combined with field potential recording. A technical note, *Stereotact Funct Neurosurg*, 2001;76:63-73.
  75. Bejjani BP, Dormont D, Pidoux B, et al., Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance, *J Neurosurg*, 2000;92:615-25.
  76. Egidi M, Rampini P, Locatelli M, et al., Visualisation of the subthalamic nucleus: a multiple sequential image fusion (MUSIF) technique for direct stereotactic localisation and postoperative control, *Neuro Sci*, 2002;23(Suppl. 2):S71-2.
  77. Alterman RL, Reiter GT, Shils J, et al., Targeting for thalamic deep brain stimulator implantation without computer guidance: assessment of targeting accuracy, *Stereotact Funct Neurosurg*, 1999;72:150-3.
  78. Coubes P, Roubertie A, Vayssiere N, et al., Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus, *Lancet*, 2000;355:2200-1.
  79. Hirabayashi H, Tengvar M, Hariz MI, Stereotactic imaging of the pallidum target, *Mov Disord*, 2002;17(Suppl. 3):S130-4.
  80. Vertinsky AT, Coenen VA, Lang DJ, et al., Localization of the subthalamic nucleus: optimization with susceptibility-weighted phase MR imaging, *AINR Am J Neuroradiol*, 2009;30:1717-24.
  81. Miyagi Y, Okamoto T, Morioka T, et al., Spectral analysis of field potential recordings by deep brain stimulation electrode for localization of subthalamic nucleus in patients with Parkinson's disease, *Stereotact Funct Neurosurg*, 2009;87:211-8.
  82. Timmermann L, Braun M, Groiss S, et al., Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson's disease, *Mov Disord*, 2008;23:218-27.
  83. Chen SY, Tsai ST, Lin SH, et al., Subthalamic deep brain stimulation in Parkinson's disease under different anesthetic modalities: a comparative cohort study, *Stereotact Funct Neurosurg*, 2011;89:372-80.
  84. Harries AM, Kausar J, Roberts SA, et al., Deep brain stimulation of the subthalamic nucleus for advanced Parkinson disease using general anesthesia: long-term results, *J Neurosurg*, 2012;116:107-13.
  85. Hertel F, Zuchner M, Weimar I, et al., Implantation of electrodes for deep brain stimulation of the subthalamic nucleus in advanced Parkinson's disease with the aid of intraoperative microrecording under general anesthesia, *Neurosurgery*, 2006;59:E1138.
  86. Guridi J, Rodriguez-Oroz MC, Lozano AM, et al., Targeting the basal ganglia for deep brain stimulation in Parkinson's disease, *Neurology*, 2000;55(12 Suppl. 6):S21-8.
  87. Zonenshayn M, Rezaei AR, Mogliner AY, et al., Comparison of anatomic and neurophysiological methods for subthalamic nucleus targeting, *Neurosurgery*, 2000;47:282-92.
  88. Starr PA, Placement of deep brain stimulators into the subthalamic nucleus or Globus pallidus internus: technical approach, *Stereotact Funct Neurosurg*, 2002;79:118-45.
  89. Krauss JK, King DE, Grossman RG, Alignment correction algorithm for transformation of stereotactic anterior commissure/posterior commissure-based coordinates into frame coordinates for image-guided functional neurosurgery, *Neurosurgery*, 1998;42:806-11.
  90. Hooper AK, Okun MS, Foote KD, et al., Venous air embolism in deep brain stimulation, *Stereotact Funct Neurosurg*, 2009;87:25-30.
  91. Deogaonkar A, Avitsian R, Henderson JM, Schubert A, Venous air embolism during deep brain stimulation surgery in an awake supine patient, *Stereotact Funct Neurosurg*, 2005;83:32-5.
  92. Moitra V, Permut TA, Penn RM, Roth S, Venous air embolism in an awake patient undergoing placement of deep brain stimulators, *J Neurosurg Anesthesiol*, 2004;16:321-2.
  93. Coenen VA, Gielen FL, Castro-Prado F, et al., Noradrenergic modulation of subthalamic nucleus activity in human: metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson's disease, *Acta Neurochir (Wien)*, 2008;150:757-62.
  94. Constantoyannis C, Berk C, Honey CR, et al., Reducing hardware-related complications of deep brain stimulation, *Can J Neurol Sci*, 2005;32:194-200.
  95. Coenen VA, Abdel-Rahman A, McMaster J, et al., Minimizing brain shift during functional neurosurgical procedures - a simple burr hole technique that can decrease CSF loss and intracranial air, *Can Eur Neurosurg*, 2011;72:181-5.
  96. Plaha P, Khan S, Gill SS, Bilateral stimulation of the caudal zona incerta nucleus for tremor control, *J Neurol Neurosurg Psychiatry*, 2008;79:504-13.
  97. Coenen VA, Madler B, Schifflbauer H, et al., Individual fiber anatomy of the subthalamic region revealed with diffusion tensor imaging: a concept to identify the deep brain stimulation target for tremor suppression, *Neurosurgery*, 2011;68:1069-75.
  98. Mercado R, Mandat T, Moore GR, et al., Three-tesla magnetic resonance imaging of the ventrolateral thalamus: a correlative anatomical description, *J Neurosurg*, 2006;105:279-83.
  99. Honey CR, Berk C, Palur RS, Schulzer M, Microelectrode recording for pallidotomy: mandatory, beneficial or dangerous?, *Stereotact Funct Neurosurg*, 2011;77:98-100.
  100. Palur RS, Berk C, Schulzer M, Honey CR, A metaanalysis comparing the results of pallidotomy performed using microelectrode recording or macroelectrode stimulation, *J Neurosurg*, 2002;96:1058-62.
  101. Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the globus pallidus interna (GPI) for treatment of advanced Parkinson's disease, *Tecnologica MAP Suppl*, 2001;1-8.
  102. Coubes P, Cif L, El Fertit H, et al., Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results, *J Neurosurg*, 2004;101:189-94.
  103. Massey LA, Yousry TA, Anatomy of the substantia nigra and subthalamic nucleus on MR imaging, *Neuroimaging Clin N Am*, 2010;20:7-27.
  104. Massey LA, Miranda MA, Zrinzo L, et al., High resolution MR anatomy of the subthalamic nucleus: imaging at 9.4T with histological validation, *Neuroimaging*, 2012;59:2035-44.
  105. Richter EO, Hoque T, Halliday W, et al., Determining the position and size of the subthalamic nucleus based on magnetic resonance imaging results in patients with advanced Parkinson disease, *J Neurosurg*, 2004;100:541-6.
  106. Caire F, Ouchchane L, Coste J, et al., Subthalamic nucleus nigra and subthalamic nucleus based stereotactic AC-PC-based diagrams and MRI anatomy-based contours, *Stereotact Funct Neurosurg*, 2009;87:337-47.
  107. Hamel W, Fietzek U, Morsnowski A, et al., Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts, *J Neurol Neurosurg Psychiatry*, 2007;74:1036-46.
  108. Lanotte MM, Rizzone M, Bergamasco B, et al., Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation, *J Neurol Neurosurg Psychiatry*, 2002;72:53-8.
  109. Rijkers K, Temel Y, Visser-Vandewalle V, et al., The microanatomical environment of the subthalamic nucleus. Technical note, *J Neurosurg*, 2007;107:198-201.
  110. Sun DA, Yu H, Spooner J, et al., Postmortem analysis following 71 months of deep brain stimulation of the subthalamic nucleus for Parkinson disease, *J Neurosurg*, 2008;109:325-9.
  111. Voges J, Volkman J, Allert N, et al., Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position, *J Neurosurg*, 2002;96:269-79.
  112. Chen CC, Lee ST, Wu T, et al., Short-term effect of bilateral subthalamic stimulation for advanced Parkinson's disease, *Chang Gung Med J*, 2003;26:344-51.
  113. Dujardin K, Defebvre L, Krystkowiak P, et al., Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease, *J Neurol*, 2001;248:603-11.
  114. Herzog J, Volkman J, Krack P, et al., Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease, *Mov Disord*, 2003;18:1332-7.
  115. Kleiner-Fisman G, Fisman DN, Sime E, et al., Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease, *J Neurosurg*, 2003;99:489-95.
  116. Lopiano L, Rizzone M, Perozzo P, et al., Deep brain stimulation of the subthalamic nucleus: selection of patients and clinical results, *Neuro Sci*, 2001;22:67-8.
  117. Pahwa R, Wilkinson SB, Overman J, Lyons KE, Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up, *J Neurosurg*, 2003;99:71-7.
  118. Simuni T, Jaggi JL, Mulholland H, et al., Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety, *J Neurosurg*, 2002;96:666-72.
  119. Thobois S, Mertens P, Guenet M, et al., Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients, *J Neurol*, 2002;249:529-34.
  120. Gross RE, Krack P, Rodriguez-Oroz MC, et al., Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor, *Mov Disord*, 2006;21(Suppl. 14):S259-83.
  121. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease, *N Engl J Med*, 2001;345:956-63.
  122. Welter M, Navarro SM, Towards standard of surgical care for DBS in PD: The GUIDE-PD Group experience (Abstract), Tenth International Congress of Parkinson's Disease and Movement Disorders, *Mov Disord*, 2006;21(Suppl. 15):S329-708.
  123. Pollak P, Fraix V, Krack P, et al., Treatment results: Parkinson's disease, *Mov Disord*, 2002;17(Suppl. 3):S75-83.
  124. Schuurman PR, Bosch DA, Bossuyt PM, et al., A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor, *N Engl J Med*, 2000;342:461-8.
  125. Umemura A, Jaggi JL, Hurttig H, et al., Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients, *J Neurosurg*, 2003;98:779-84.
  126. Oh MY, Abosch A, Kim SH, et al., Long-term hardware-related complications of deep brain stimulation, *Neurosurgery*, 2002;50:1268-74.
  127. Hamani C, Lozano AM, Hardware-related complications of deep brain stimulation: a review of the published literature, *Stereotact Funct Neurosurg*, 2006;84:248-51.
  128. Beric A, Kelly PJ, Rezaei A, et al., Complications of deep brain stimulation surgery, *Stereotact Funct Neurosurg*, 2001;77:73-8.
  129. Hariz MI, Reihncrona S, Quinn NP, et al., Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years, *Mov Disord*, 2008;23:416-21.
  130. Vergani F, Landi A, Pirillo D, et al., Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease, *World Neurosurg*, 2010;73:338-44.
  131. Benabid AL, Pollak P, Seigneuret E, et al., Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias, *Acta Neurochir Suppl (Wien)*, 1993;58:39-44.
  132. Koller W, Pahwa R, Busenbark K, et al., High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor, *Ann Neurol*, 1997;42:292-9.
  133. Limousin P, Speelman JD, Gielen F, Janssens M, Multicentre European study of thalamic stimulation in parkinsonian and essential tremor, *J Neurol Neurosurg Psychiatry*, 1999;66:289-96.
  134. Pahwa R, Lyons KE, Wilkinson SB, et al., Long-term evaluation of deep brain stimulation of the thalamus, *J Neurosurg*, 2006;104:506-12.
  135. Kumar R, Lang AE, Rodriguez-Oroz MC, et al., Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease, *Neurology*, 2000;55(12 Suppl. 6):S34-9.
  136. Volkman J, Allert N, Voges J, et al., Long-term results of bilateral pallidum stimulation in Parkinson's disease, *Ann Neurol*, 2004;55:871-5.
  137. Lohrer TJ, Burgunder JM, Pohle T, et al., Long-term pallidum deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study, *J Neurosurg*, 2002;96:844-53.
  138. Rodrigues JP, Walters SE, Watson P, et al., Globus pallidus stimulation in advanced Parkinson's disease, *J Clin Neurosci*, 2007;14:208-15.
  139. Moro E, Lozano AM, Pollak P, et al., Long-term results of a multicenter study on subthalamic and pallidum stimulation in Parkinson's disease, *Mov Disord*, 2010;25:578-86.
  140. Hariz MI, Reihncrona S, Quinn NP, et al., Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years, *Mov Disord*, 2008;23:416-21.
  141. Rodriguez-Oroz MC, Zamarbide I, Guridi J, et al., Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation, *J Neurol Neurosurg Psychiatry*, 2004;75:1382-5.
  142. Limousin P, Pollak P, Benazzouk A, et al., Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation, *Lancet*, 1995;345:91-5.
  143. Limousin P, Krack P, Pollak P, et al., Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease, *N Engl J Med*, 1998;339:1105-11.
  144. Krack P, Limousin P, Benabid AL, Pollak P, Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease, *Lancet*, 1997;350:1676.
  145. Kleiner-Fisman G, Herzog J, Fisman DN, et al., Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes, *Mov Disord*, 2006;21(Suppl. 14):S290-304.
  146. Voon V, Krack P, Lang AE, et al., A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease, *Brain*, 2008;131:2720-8.